

truncation threshold: 0.05

Outcome: Attendance to the mammogram invitation during the following 12 months

Subgroup:

CD002943

Study	Intervention		Control		Weight	Odds Ratio Peto, Fixed, 95% CI
	Events	Total	Events	Total		
Sutton–1994	576	977	167	316	32.3%	1.28 [0.99; 1.66]
Somkin–1997	310	1171	187	1171	54.2%	1.87 [1.54; 2.28]
Turnbull–1991	53	163	7	80	5.5%	3.57 [1.92; 6.63]
Mohler–1995	7	38	4	38	1.3%	1.88 [0.53; 6.68]
Bodiya–1999	36	102	37	110	6.6%	1.08 [0.61; 1.89]


Total (95% CI) **2451** **1715 100.0%** **1.66 [1.43; 1.92]**

Heterogeneity: $\text{Tau}^2 = 0.0882$; $\text{Chi}^2 = 13.47$, $\text{df} = 4$ ($P < 0.01$); $I^2 = 70\%$

Test for overall effect: $Z = 6.78$ ($P < 0.0001$)

Replicability analysis ($r\text{-value} = < 0.0001$)

Out of 5 studies, at least: 3 with increased effect and 0 with decreased effect.



Outcome: Attendance to the mammogram invitation during the following 12 months

Subgroup:

CD002943


Study	Intervention		Control		Weight	Odds Ratio Peto, Fixed, 95% CI
	Events	Total	Events	Total		
Bodiya–1999	49	86	37	110	15.8%	2.57 [1.46; 4.53]
Janz–1997	178	316	119	319	52.5%	2.14 [1.57; 2.93]
Lantz–1995	88	337	28	322	31.7%	3.32 [2.22; 4.95]
Total (95% CI)		739		751	100.0%	2.53 [2.02; 3.18]

Heterogeneity: $\text{Tau}^2 = 0.0185$; $\text{Chi}^2 = 2.84$, $\text{df} = 2$ ($P = 0.24$); $I^2 = 30\%$

Test for overall effect: $Z = 8.08$ ($P < 0.0001$)

Replicability analysis ($r\text{-value} = < 0.0001$)

Out of 3 studies, at least: 3 with increased effect and 0 with decreased effect.



Outcome: Leukopaenia: overall effect

Subgroup:

CD003366

Study	Taxane containing		Control		Weight	Risk Ratio MH, Random, 95% CI
	Events	Total	Events	Total		
ECOG-E1193-_x0028_A_x0029_	126	230	56	112	4.4%	1.10 [0.88; 1.36]
EU_x002d_93011	76	85	53	85	4.8%	1.43 [1.20; 1.72]
_x0033_06-Study-Group	202	213	184	210	5.7%	1.08 [1.02; 1.15]
AGO	69	204	89	198	4.1%	0.75 [0.59; 0.96]
Blohmer	101	125	82	111	5.2%	1.09 [0.95; 1.26]
Bonneterre	31	70	24	72	2.6%	1.33 [0.87; 2.02]
Bontenbal	96	108	90	107	5.4%	1.06 [0.95; 1.17]
CECOG-BM1	113	122	109	130	5.6%	1.10 [1.01; 1.21]
EORTC-10961	121	136	110	135	5.5%	1.09 [0.99; 1.21]
HERNATA	56	139	29	138	2.9%	1.92 [1.31; 2.81]
Jassem	119	134	87	133	5.2%	1.36 [1.18; 1.56]
Lyman	31	45	32	46	3.8%	0.99 [0.75; 1.30]
Nabholtz	224	238	192	237	5.7%	1.16 [1.08; 1.25]
Rugo	3	32	3	45	0.3%	1.41 [0.30; 6.53]
TRAVIOTA	4	40	24	41	0.8%	0.17 [0.07; 0.45]
_x0033_03-Study-Group	154	159	153	163	5.8%	1.03 [0.98; 1.08]
_x0033_04-Study-Group	188	200	176	187	5.8%	1.00 [0.95; 1.05]
ANZ-TITG	31	105	67	99	3.3%	0.44 [0.32; 0.60]
Dieras	8	38	2	39	0.4%	4.11 [0.93; 18.10]
ECOG-E1193-_x0028_B_x0029_	137	229	55	112	4.4%	1.22 [0.98; 1.51]
EORTC-10923	66	164	139	163	4.6%	0.47 [0.39; 0.57]
JCOG9802	50	147	31	146	2.9%	1.60 [1.09; 2.35]
Meier	9	58	39	62	1.5%	0.25 [0.13; 0.46]
Sjostrom	105	136	21	131	2.7%	4.82 [3.22; 7.20]
Talbot	10	19	2	22	0.4%	5.79 [1.44; 23.21]
TOG	11	97	18	96	1.3%	0.60 [0.30; 1.21]
TXT	65	79	60	90	4.8%	1.23 [1.03; 1.48]
Yardley	1	52	5	50	0.2%	0.19 [0.02; 1.59]


Total (95% CI) **3404** **3160 100.0%** **1.07 [0.97; 1.17]**

Heterogeneity: $\tau^2 = 0.0365$; $\chi^2 = 261.41$, $df = 27$ ($P < 0.01$); $I^2 = 90\%$

Test for overall effect: $Z = 1.41$ ($P = 0.1596$)

Replicability analysis (r -value = < 0.0001)

Out of 28 studies, at least: 13 with increased effect and 5 with decreased effect.



Outcome: Leukopaenia: overall effect

Subgroup: Regimen A plus taxane v Regimen B

CD003366

Study	Taxane containing		Control		Weight	Risk Ratio MH, Random, 95% CI
	Events	Total	Events	Total		
_x0033_06--Study-Group	202	213	184	210	13.4%	1.08 [1.02; 1.15]
AGO	69	204	89	198	6.0%	0.75 [0.59; 0.96]
Bloher	101	125	82	111	9.9%	1.09 [0.95; 1.26]
Bonneterre	31	70	24	72	2.8%	1.33 [0.87; 2.02]
Bontenbal	96	108	90	107	11.5%	1.06 [0.95; 1.17]
CECOG-BM1	113	122	109	130	12.1%	1.10 [1.01; 1.21]
EORTC-10961	121	136	110	135	11.7%	1.09 [0.99; 1.21]
HERNATA	56	139	29	138	3.3%	1.92 [1.31; 2.81]
Jassem	119	134	87	133	10.0%	1.36 [1.18; 1.56]
Lyman	31	45	32	46	5.3%	0.99 [0.75; 1.30]
Nabholtz	224	238	192	237	13.0%	1.16 [1.08; 1.25]
Rugo	3	32	3	45	0.3%	1.41 [0.30; 6.53]
TRAVIOTA	4	40	24	41	0.6%	0.17 [0.07; 0.45]


Total (95% CI) **1606** **1603 100.0%** **1.11 [1.02; 1.20]**

Heterogeneity: $\text{Tau}^2 = 0.0112$; $\text{Chi}^2 = 45.34$, $\text{df} = 12$ ($P < 0.01$); $I^2 = 74\%$

Test for overall effect: $Z = 2.49$ ($P = 0.0128$)

Replicability analysis ($r\text{-value} = < 0.0001$)

Out of 13 studies, at least: 6 with increased effect and 2 with decreased effect.



Outcome: Leukopaenia: overall effect

Subgroup: Single agent taxane v Regimen C

CD003366

Study	Taxane containing		Control		Weight	Risk Ratio MH, Random, 95% CI
	Events	Total	Events	Total		
_x0033_03-Study-Group	154	159	153	163	12.6%	1.03 [0.98; 1.08]
_x0033_04-Study-Group	188	200	176	187	12.6%	1.00 [0.95; 1.05]
ANZ-TITG	31	105	67	99	9.5%	0.44 [0.32; 0.60]
Dieras	8	38	2	39	1.6%	4.11 [0.93; 18.10]
ECOG-E1193-_x0028_B_x0029_	137	229	55	112	11.0%	1.22 [0.98; 1.51]
EORTC-10923	66	164	139	163	11.3%	0.47 [0.39; 0.57]
JCOG9802	50	147	31	146	8.6%	1.60 [1.09; 2.35]
Meier	9	58	39	62	5.6%	0.25 [0.13; 0.46]
Sjostrom	105	136	21	131	8.3%	4.82 [3.22; 7.20]
Talbot	10	19	2	22	1.8%	5.79 [1.44; 23.21]
TOG	11	97	18	96	5.0%	0.60 [0.30; 1.21]
TXT	65	79	60	90	11.5%	1.23 [1.03; 1.48]
Yardley	1	52	5	50	0.8%	0.19 [0.02; 1.59]


Total (95% CI) **1483** **1360 100.0%** **0.99 [0.82; 1.21]**

Heterogeneity: $\text{Tau}^2 = 0.0813$; $\text{Chi}^2 = 188.43$, $\text{df} = 12$ ($P < 0.01$); $I^2 = 94\%$

Test for overall effect: $Z = -0.05$ ($P = 0.9587$)

Replicability analysis ($r\text{-value} = < 0.0001$)

Out of 13 studies, at least: 6 with increased effect and 3 with decreased effect.



Outcome: Seroma

Subgroup:

CD006823

Study	Drain		No .		Weight	Odds Ratio MH, Random, 95% CI
	Events	Total	Events	Total		
Cameron–1988	2	20	9	20	10.0%	0.14 [0.02; 0.75]
Somers–1992	79	108	106	119	20.1%	0.33 [0.16; 0.68]
Zavotksy–1998	0	24	14	22	4.6%	0.01 [0.00; 0.22]
Purushotham–2002	98	190	98	185	23.6%	0.95 [0.63; 1.42]
Jain–2004	15	58	12	29	17.4%	0.49 [0.19; 1.27]
Soon–2005	34	36	49	51	8.1%	0.69 [0.09; 5.17]
Classe–2006	9	51	8	47	16.2%	1.04 [0.37; 2.98]


Total (95% CI) **487** **473 100.0%** **0.46 [0.23; 0.91]**

Heterogeneity: $\text{Tau}^2 = 0.4833$; $\text{Chi}^2 = 18.58$, $\text{df} = 6$ ($P < 0.01$); $I^2 = 68\%$

Test for overall effect: $Z = -2.22$ ($P = 0.0266$)

Replicability analysis ($r\text{-value} = 0.0052$)

Out of 7 studies, at least: 0 with increased effect and 3 with decreased effect.



Outcome: Cosmesis, physician–reported

Subgroup:

CD007077

Study	PBI/APBI		WBRT		Weight	Odds Ratio MH, Fixed, 95% CI
	Events	Total	Events	Total		
Livi-2015	0	246	2	260	2.5%	0.21 [0.01; 4.39]
Polg_x00e1_r-2007	24	125	43	116	37.4%	0.40 [0.23; 0.72]
RAPID	140	399	61	367	42.8%	2.71 [1.92; 3.82]
Rodriguez	12	51	8	51	6.3%	1.65 [0.61; 4.47]
TARGIT	12	55	13	50	11.0%	0.79 [0.32; 1.95]


Total (95% CI) **876** **844 100.0%** **1.51 [1.17; 1.95]**

Heterogeneity: $\text{Tau}^2 = 1.0240$; $\text{Chi}^2 = 34.47$, $\text{df} = 4$ ($P < 0.01$); $I^2 = 88\%$

Test for overall effect: $Z = 3.14$ ($P = 0.0017$)

Replicability analysis ($r\text{-value} = 1$)

Out of 5 studies, at least: 1 with increased effect and 1 with decreased effect.



truncation threshold: 0.1

Outcome: Attendance to the mammogram invitation during the following 12 months

Subgroup:

CD002943

Study	Intervention		Control		Weight	Odds Ratio Peto, Fixed, 95% CI
	Events	Total	Events	Total		
Sutton–1994	576	977	167	316	32.3%	1.28 [0.99; 1.66]
Somkin–1997	310	1171	187	1171	54.2%	1.87 [1.54; 2.28]
Turnbull–1991	53	163	7	80	5.5%	3.57 [1.92; 6.63]
Mohler–1995	7	38	4	38	1.3%	1.88 [0.53; 6.68]
Bodiya–1999	36	102	37	110	6.6%	1.08 [0.61; 1.89]


Total (95% CI) **2451** **1715 100.0%** **1.66 [1.43; 1.92]**

Heterogeneity: $\text{Tau}^2 = 0.0882$; $\text{Chi}^2 = 13.47$, $\text{df} = 4$ ($P < 0.01$); $I^2 = 70\%$

Test for overall effect: $Z = 6.78$ ($P < 0.0001$)

Replicability analysis ($r\text{-value} = < 0.0001$)

Out of 5 studies, at least: 3 with increased effect and 0 with decreased effect.



Outcome: Attendance to the mammogram invitation during the following 12 months

Subgroup:

CD002943


Study	Intervention		Control		Weight	Odds Ratio Peto, Fixed, 95% CI
	Events	Total	Events	Total		
Bodiya–1999	49	86	37	110	15.8%	2.57 [1.46; 4.53]
Janz–1997	178	316	119	319	52.5%	2.14 [1.57; 2.93]
Lantz–1995	88	337	28	322	31.7%	3.32 [2.22; 4.95]
Total (95% CI)		739		751	100.0%	2.53 [2.02; 3.18]

Heterogeneity: $\text{Tau}^2 = 0.0185$; $\text{Chi}^2 = 2.84$, $\text{df} = 2$ ($P = 0.24$); $I^2 = 30\%$

Test for overall effect: $Z = 8.08$ ($P < 0.0001$)

Replicability analysis ($r\text{-value} = < 0.0001$)

Out of 3 studies, at least: 3 with increased effect and 0 with decreased effect.



Outcome: Leukopaenia: overall effect

Subgroup:

CD003366

Study	Taxane containing		Control		Weight	Risk Ratio MH, Random, 95% CI
	Events	Total	Events	Total		
ECOG-E1193-_x0028_A_x0029_	126	230	56	112	4.4%	1.10 [0.88; 1.36]
EU_x002d_93011	76	85	53	85	4.8%	1.43 [1.20; 1.72]
_x0033_06-Study-Group	202	213	184	210	5.7%	1.08 [1.02; 1.15]
AGO	69	204	89	198	4.1%	0.75 [0.59; 0.96]
Blohmer	101	125	82	111	5.2%	1.09 [0.95; 1.26]
Bonneterre	31	70	24	72	2.6%	1.33 [0.87; 2.02]
Bontenbal	96	108	90	107	5.4%	1.06 [0.95; 1.17]
CECOG-BM1	113	122	109	130	5.6%	1.10 [1.01; 1.21]
EORTC-10961	121	136	110	135	5.5%	1.09 [0.99; 1.21]
HERNATA	56	139	29	138	2.9%	1.92 [1.31; 2.81]
Jassem	119	134	87	133	5.2%	1.36 [1.18; 1.56]
Lyman	31	45	32	46	3.8%	0.99 [0.75; 1.30]
Nabholtz	224	238	192	237	5.7%	1.16 [1.08; 1.25]
Rugo	3	32	3	45	0.3%	1.41 [0.30; 6.53]
TRAVIOTA	4	40	24	41	0.8%	0.17 [0.07; 0.45]
_x0033_03-Study-Group	154	159	153	163	5.8%	1.03 [0.98; 1.08]
_x0033_04-Study-Group	188	200	176	187	5.8%	1.00 [0.95; 1.05]
ANZ-TITG	31	105	67	99	3.3%	0.44 [0.32; 0.60]
Dieras	8	38	2	39	0.4%	4.11 [0.93; 18.10]
ECOG-E1193-_x0028_B_x0029_	137	229	55	112	4.4%	1.22 [0.98; 1.51]
EORTC-10923	66	164	139	163	4.6%	0.47 [0.39; 0.57]
JCOG9802	50	147	31	146	2.9%	1.60 [1.09; 2.35]
Meier	9	58	39	62	1.5%	0.25 [0.13; 0.46]
Sjostrom	105	136	21	131	2.7%	4.82 [3.22; 7.20]
Talbot	10	19	2	22	0.4%	5.79 [1.44; 23.21]
TOG	11	97	18	96	1.3%	0.60 [0.30; 1.21]
TXT	65	79	60	90	4.8%	1.23 [1.03; 1.48]
Yardley	1	52	5	50	0.2%	0.19 [0.02; 1.59]


Total (95% CI) **3404** **3160 100.0%** **1.07 [0.97; 1.17]**

Heterogeneity: $\tau^2 = 0.0365$; $\chi^2 = 261.41$, $df = 27$ ($P < 0.01$); $I^2 = 90\%$

Test for overall effect: $Z = 1.41$ ($P = 0.1596$)

Replicability analysis (r -value = < 0.0001)

Out of 28 studies, at least: 14 with increased effect and 7 with decreased effect.



Outcome: Leukopaenia: overall effect

Subgroup: Regimen A plus taxane v Regimen B

CD003366

Study	Taxane containing		Control		Weight	Risk Ratio MH, Random, 95% CI
	Events	Total	Events	Total		
_x0033_06--Study-Group	202	213	184	210	13.4%	1.08 [1.02; 1.15]
AGO	69	204	89	198	6.0%	0.75 [0.59; 0.96]
Blohmmer	101	125	82	111	9.9%	1.09 [0.95; 1.26]
Bonneterre	31	70	24	72	2.8%	1.33 [0.87; 2.02]
Bontenbal	96	108	90	107	11.5%	1.06 [0.95; 1.17]
CECOG-BM1	113	122	109	130	12.1%	1.10 [1.01; 1.21]
EORTC-10961	121	136	110	135	11.7%	1.09 [0.99; 1.21]
HERNATA	56	139	29	138	3.3%	1.92 [1.31; 2.81]
Jassem	119	134	87	133	10.0%	1.36 [1.18; 1.56]
Lyman	31	45	32	46	5.3%	0.99 [0.75; 1.30]
Nabholtz	224	238	192	237	13.0%	1.16 [1.08; 1.25]
Rugo	3	32	3	45	0.3%	1.41 [0.30; 6.53]
TRAVIOTA	4	40	24	41	0.6%	0.17 [0.07; 0.45]


Total (95% CI) **1606** **1603 100.0%** **1.11 [1.02; 1.20]**

Heterogeneity: $\text{Tau}^2 = 0.0112$; $\text{Chi}^2 = 45.34$, $\text{df} = 12$ ($P < 0.01$); $I^2 = 74\%$

Test for overall effect: $Z = 2.49$ ($P = 0.0128$)

Replicability analysis (r -value = < 0.0001)

Out of 13 studies, at least: 7 with increased effect and 2 with decreased effect.



Outcome: Leukopaenia: overall effect

Subgroup: Single agent taxane v Regimen C

CD003366

Study	Taxane containing		Control		Weight	Risk Ratio MH, Random, 95% CI
	Events	Total	Events	Total		
_x0033_03-Study-Group	154	159	153	163	12.6%	1.03 [0.98; 1.08]
_x0033_04-Study-Group	188	200	176	187	12.6%	1.00 [0.95; 1.05]
ANZ-TITG	31	105	67	99	9.5%	0.44 [0.32; 0.60]
Dieras	8	38	2	39	1.6%	4.11 [0.93; 18.10]
ECOG-E1193-_x0028_B_x0029_	137	229	55	112	11.0%	1.22 [0.98; 1.51]
EORTC-10923	66	164	139	163	11.3%	0.47 [0.39; 0.57]
JCOG9802	50	147	31	146	8.6%	1.60 [1.09; 2.35]
Meier	9	58	39	62	5.6%	0.25 [0.13; 0.46]
Sjostrom	105	136	21	131	8.3%	4.82 [3.22; 7.20]
Talbot	10	19	2	22	1.8%	5.79 [1.44; 23.21]
TOG	11	97	18	96	5.0%	0.60 [0.30; 1.21]
TXT	65	79	60	90	11.5%	1.23 [1.03; 1.48]
Yardley	1	52	5	50	0.8%	0.19 [0.02; 1.59]


Total (95% CI) **1483** **1360 100.0%** **0.99 [0.82; 1.21]**

Heterogeneity: $\text{Tau}^2 = 0.0813$; $\text{Chi}^2 = 188.43$, $\text{df} = 12$ ($P < 0.01$); $I^2 = 94\%$

Test for overall effect: $Z = -0.05$ ($P = 0.9587$)

Replicability analysis ($r\text{-value} = < 0.0001$)

Out of 13 studies, at least: 6 with increased effect and 5 with decreased effect.



Outcome: Seroma

Subgroup:

CD006823

Study	Drain		No .		Weight	Odds Ratio MH, Random, 95% CI
	Events	Total	Events	Total		
Cameron–1988	2	20	9	20	10.0%	0.14 [0.02; 0.75]
Somers–1992	79	108	106	119	20.1%	0.33 [0.16; 0.68]
Zavotksy–1998	0	24	14	22	4.6%	0.01 [0.00; 0.22]
Purushotham–2002	98	190	98	185	23.6%	0.95 [0.63; 1.42]
Jain–2004	15	58	12	29	17.4%	0.49 [0.19; 1.27]
Soon–2005	34	36	49	51	8.1%	0.69 [0.09; 5.17]
Classe–2006	9	51	8	47	16.2%	1.04 [0.37; 2.98]


Total (95% CI) **487** **473 100.0%** **0.46 [0.23; 0.91]**

Heterogeneity: $\text{Tau}^2 = 0.4833$; $\text{Chi}^2 = 18.58$, $\text{df} = 6$ ($P < 0.01$); $I^2 = 68\%$

Test for overall effect: $Z = -2.22$ ($P = 0.0266$)

Replicability analysis ($r\text{-value} = 0.0021$)

Out of 7 studies, at least: 0 with increased effect and 4 with decreased effect.



Outcome: Cosmesis, physician-reported

Subgroup:

CD007077

Study	PBI/APBI		WBRT		Weight	Odds Ratio MH, Fixed, 95% CI
	Events	Total	Events	Total		
Livi-2015	0	246	2	260	2.5%	0.21 [0.01; 4.39]
Polg_x00e1_r-2007	24	125	43	116	37.4%	0.40 [0.23; 0.72]
RAPID	140	399	61	367	42.8%	2.71 [1.92; 3.82]
Rodriguez	12	51	8	51	6.3%	1.65 [0.61; 4.47]
TARGIT	12	55	13	50	11.0%	0.79 [0.32; 1.95]


Total (95% CI) **876** **844 100.0%** **1.51 [1.17; 1.95]**

Heterogeneity: $\text{Tau}^2 = 1.0240$; $\text{Chi}^2 = 34.47$, $\text{df} = 4$ ($P < 0.01$); $I^2 = 88\%$

Test for overall effect: $Z = 3.14$ ($P = 0.0017$)

Replicability analysis ($r\text{-value} = 1$)

Out of 5 studies, at least: 1 with increased effect and 1 with decreased effect.



truncation threshold: 0.2

Outcome: Attendance to the mammogram invitation during the following 12 months

Subgroup:

CD002943

Study	Intervention		Control		Weight	Odds Ratio Peto, Fixed, 95% CI
	Events	Total	Events	Total		
Sutton–1994	576	977	167	316	32.3%	1.28 [0.99; 1.66]
Somkin–1997	310	1171	187	1171	54.2%	1.87 [1.54; 2.28]
Turnbull–1991	53	163	7	80	5.5%	3.57 [1.92; 6.63]
Mohler–1995	7	38	4	38	1.3%	1.88 [0.53; 6.68]
Bodiya–1999	36	102	37	110	6.6%	1.08 [0.61; 1.89]


Total (95% CI) **2451** **1715 100.0%** **1.66 [1.43; 1.92]**

Heterogeneity: $\text{Tau}^2 = 0.0882$; $\text{Chi}^2 = 13.47$, $\text{df} = 4$ ($P < 0.01$); $I^2 = 70\%$

Test for overall effect: $Z = 6.78$ ($P < 0.0001$)

Replicability analysis (r -value = < 0.0001)

Out of 5 studies, at least: 4 with increased effect and 0 with decreased effect.



Outcome: Attendance to the mammogram invitation during the following 12 months

Subgroup:

CD002943


Study	Intervention		Control		Weight	Odds Ratio Peto, Fixed, 95% CI
	Events	Total	Events	Total		
Bodiya–1999	49	86	37	110	15.8%	2.57 [1.46; 4.53]
Janz–1997	178	316	119	319	52.5%	2.14 [1.57; 2.93]
Lantz–1995	88	337	28	322	31.7%	3.32 [2.22; 4.95]
Total (95% CI)		739		751	100.0%	2.53 [2.02; 3.18]

Heterogeneity: $\text{Tau}^2 = 0.0185$; $\text{Chi}^2 = 2.84$, $\text{df} = 2$ ($P = 0.24$); $I^2 = 30\%$

Test for overall effect: $Z = 8.08$ ($P < 0.0001$)

Replicability analysis ($r\text{-value} = < 0.0001$)

Out of 3 studies, at least: 3 with increased effect and 0 with decreased effect.



Outcome: Leukopaenia: overall effect

Subgroup:

CD003366

Study	Taxane containing		Control		Weight	Risk Ratio MH, Random, 95% CI
	Events	Total	Events	Total		
ECOG-E1193-_x0028_A_x0029_	126	230	56	112	4.4%	1.10 [0.88; 1.36]
EU_x002d_93011	76	85	53	85	4.8%	1.43 [1.20; 1.72]
_x0033_06-Study-Group	202	213	184	210	5.7%	1.08 [1.02; 1.15]
AGO	69	204	89	198	4.1%	0.75 [0.59; 0.96]
Blohmer	101	125	82	111	5.2%	1.09 [0.95; 1.26]
Bonneterre	31	70	24	72	2.6%	1.33 [0.87; 2.02]
Bontenbal	96	108	90	107	5.4%	1.06 [0.95; 1.17]
CECOG-BM1	113	122	109	130	5.6%	1.10 [1.01; 1.21]
EORTC-10961	121	136	110	135	5.5%	1.09 [0.99; 1.21]
HERNATA	56	139	29	138	2.9%	1.92 [1.31; 2.81]
Jassem	119	134	87	133	5.2%	1.36 [1.18; 1.56]
Lyman	31	45	32	46	3.8%	0.99 [0.75; 1.30]
Nabholtz	224	238	192	237	5.7%	1.16 [1.08; 1.25]
Rugo	3	32	3	45	0.3%	1.41 [0.30; 6.53]
TRAVIOTA	4	40	24	41	0.8%	0.17 [0.07; 0.45]
_x0033_03-Study-Group	154	159	153	163	5.8%	1.03 [0.98; 1.08]
_x0033_04-Study-Group	188	200	176	187	5.8%	1.00 [0.95; 1.05]
ANZ-TITG	31	105	67	99	3.3%	0.44 [0.32; 0.60]
Dieras	8	38	2	39	0.4%	4.11 [0.93; 18.10]
ECOG-E1193-_x0028_B_x0029_	137	229	55	112	4.4%	1.22 [0.98; 1.51]
EORTC-10923	66	164	139	163	4.6%	0.47 [0.39; 0.57]
JCOG9802	50	147	31	146	2.9%	1.60 [1.09; 2.35]
Meier	9	58	39	62	1.5%	0.25 [0.13; 0.46]
Sjostrom	105	136	21	131	2.7%	4.82 [3.22; 7.20]
Talbot	10	19	2	22	0.4%	5.79 [1.44; 23.21]
TOG	11	97	18	96	1.3%	0.60 [0.30; 1.21]
TXT	65	79	60	90	4.8%	1.23 [1.03; 1.48]
Yardley	1	52	5	50	0.2%	0.19 [0.02; 1.59]


Total (95% CI) **3404** **3160 100.0%** **1.07 [0.97; 1.17]**

Heterogeneity: $\tau^2 = 0.0365$; $\chi^2 = 261.41$, $df = 27$ ($P < 0.01$); $I^2 = 90\%$

Test for overall effect: $Z = 1.41$ ($P = 0.1596$)

Replicability analysis (r -value = < 0.0001)

Out of 28 studies, at least: 17 with increased effect and 7 with decreased effect.



Outcome: Leukopaenia: overall effect

Subgroup: Regimen A plus taxane v Regimen B

CD003366

Study	Taxane containing		Control		Weight	Risk Ratio MH, Random, 95% CI
	Events	Total	Events	Total		
_x0033_06--Study-Group	202	213	184	210	13.4%	1.08 [1.02; 1.15]
AGO	69	204	89	198	6.0%	0.75 [0.59; 0.96]
Blohmer	101	125	82	111	9.9%	1.09 [0.95; 1.26]
Bonneterre	31	70	24	72	2.8%	1.33 [0.87; 2.02]
Bontenbal	96	108	90	107	11.5%	1.06 [0.95; 1.17]
CECOG-BM1	113	122	109	130	12.1%	1.10 [1.01; 1.21]
EORTC-10961	121	136	110	135	11.7%	1.09 [0.99; 1.21]
HERNATA	56	139	29	138	3.3%	1.92 [1.31; 2.81]
Jassem	119	134	87	133	10.0%	1.36 [1.18; 1.56]
Lyman	31	45	32	46	5.3%	0.99 [0.75; 1.30]
Nabholtz	224	238	192	237	13.0%	1.16 [1.08; 1.25]
Rugo	3	32	3	45	0.3%	1.41 [0.30; 6.53]
TRAVIOTA	4	40	24	41	0.6%	0.17 [0.07; 0.45]

Total (95% CI)

1606

1603 100.0%


1.11 [1.02; 1.20]

Heterogeneity: $\text{Tau}^2 = 0.0112$; $\text{Chi}^2 = 45.34$, $\text{df} = 12$ ($P < 0.01$); $I^2 = 74\%$

Test for overall effect: $Z = 2.49$ ($P = 0.0128$)

Replicability analysis ($r\text{-value} = < 0.0001$)

Out of 13 studies, at least: 9 with increased effect and 2 with decreased effect.



Outcome: Leukopaenia: overall effect

Subgroup: Single agent taxane v Regimen C

CD003366


Study	Taxane containing		Control		Weight	Risk Ratio MH, Random, 95% CI
	Events	Total	Events	Total		
_x0033_03-Study-Group	154	159	153	163	12.6%	1.03 [0.98; 1.08]
_x0033_04-Study-Group	188	200	176	187	12.6%	1.00 [0.95; 1.05]
ANZ-TITG	31	105	67	99	9.5%	0.44 [0.32; 0.60]
Dieras	8	38	2	39	1.6%	4.11 [0.93; 18.10]
ECOG-E1193-_x0028_B_x0029_	137	229	55	112	11.0%	1.22 [0.98; 1.51]
EORTC-10923	66	164	139	163	11.3%	0.47 [0.39; 0.57]
JCOG9802	50	147	31	146	8.6%	1.60 [1.09; 2.35]
Meier	9	58	39	62	5.6%	0.25 [0.13; 0.46]
Sjostrom	105	136	21	131	8.3%	4.82 [3.22; 7.20]
Talbot	10	19	2	22	1.8%	5.79 [1.44; 23.21]
TOG	11	97	18	96	5.0%	0.60 [0.30; 1.21]
TXT	65	79	60	90	11.5%	1.23 [1.03; 1.48]
Yardley	1	52	5	50	0.8%	0.19 [0.02; 1.59]
Total (95% CI)		1483		1360 100.0%		0.99 [0.82; 1.21]

Heterogeneity: $\text{Tau}^2 = 0.0813$; $\text{Chi}^2 = 188.43$, $\text{df} = 12$ ($P < 0.01$); $I^2 = 94\%$

Test for overall effect: $Z = -0.05$ ($P = 0.9587$)

Replicability analysis ($r\text{-value} = < 0.0001$)

Out of 13 studies, at least: 7 with increased effect and 5 with decreased effect.



Outcome: Seroma

Subgroup:

CD006823

Study	Drain		No .		Weight	Odds Ratio MH, Random, 95% CI
	Events	Total	Events	Total		
Cameron–1988	2	20	9	20	10.0%	0.14 [0.02; 0.75]
Somers–1992	79	108	106	119	20.1%	0.33 [0.16; 0.68]
Zavotksy–1998	0	24	14	22	4.6%	0.01 [0.00; 0.22]
Purushotham–2002	98	190	98	185	23.6%	0.95 [0.63; 1.42]
Jain–2004	15	58	12	29	17.4%	0.49 [0.19; 1.27]
Soon–2005	34	36	49	51	8.1%	0.69 [0.09; 5.17]
Classe–2006	9	51	8	47	16.2%	1.04 [0.37; 2.98]


Total (95% CI) **487** **473 100.0%** **0.46 [0.23; 0.91]**

Heterogeneity: $\text{Tau}^2 = 0.4833$; $\text{Chi}^2 = 18.58$, $\text{df} = 6$ ($P < 0.01$); $I^2 = 68\%$

Test for overall effect: $Z = -2.22$ ($P = 0.0266$)

Replicability analysis ($r\text{-value} = 0.0044$)

Out of 7 studies, at least: 0 with increased effect and 4 with decreased effect.



Outcome: Cosmesis, physician–reported

Subgroup:

CD007077

Study	PBI/APBI		WBRT		Weight	Odds Ratio MH, Fixed, 95% CI
	Events	Total	Events	Total		
Livi-2015	0	246	2	260	2.5%	0.21 [0.01; 4.39]
Polg_x00e1_r-2007	24	125	43	116	37.4%	0.40 [0.23; 0.72]
RAPID	140	399	61	367	42.8%	2.71 [1.92; 3.82]
Rodriguez	12	51	8	51	6.3%	1.65 [0.61; 4.47]
TARGIT	12	55	13	50	11.0%	0.79 [0.32; 1.95]


Total (95% CI) **876** **844 100.0%** **1.51 [1.17; 1.95]**

Heterogeneity: $\text{Tau}^2 = 1.0240$; $\text{Chi}^2 = 34.47$, $\text{df} = 4$ ($P < 0.01$); $I^2 = 88\%$

Test for overall effect: $Z = 3.14$ ($P = 0.0017$)

Replicability analysis ($r\text{-value} = 0.3142$)

Out of 5 studies, at least: 2 with increased effect and 2 with decreased effect.



truncation threshold: 0.6

Outcome: Attendance to the mammogram invitation during the following 12 months

Subgroup:

CD002943

Study	Intervention		Control		Weight	Odds Ratio Peto, Fixed, 95% CI
	Events	Total	Events	Total		
Sutton–1994	576	977	167	316	32.3%	1.28 [0.99; 1.66]
Somkin–1997	310	1171	187	1171	54.2%	1.87 [1.54; 2.28]
Turnbull–1991	53	163	7	80	5.5%	3.57 [1.92; 6.63]
Mohler–1995	7	38	4	38	1.3%	1.88 [0.53; 6.68]
Bodiya–1999	36	102	37	110	6.6%	1.08 [0.61; 1.89]


Total (95% CI) **2451** **1715 100.0%** **1.66 [1.43; 1.92]**

Heterogeneity: $\text{Tau}^2 = 0.0882$; $\text{Chi}^2 = 13.47$, $\text{df} = 4$ ($P < 0.01$); $I^2 = 70\%$

Test for overall effect: $Z = 6.78$ ($P < 0.0001$)

Replicability analysis (r -value = < 0.0001)

Out of 5 studies, at least: 5 with increased effect and 0 with decreased effect.



Outcome: Attendance to the mammogram invitation during the following 12 months

Subgroup:

CD002943


Study	Intervention		Control		Weight	Odds Ratio Peto, Fixed, 95% CI
	Events	Total	Events	Total		
Bodiya–1999	49	86	37	110	15.8%	2.57 [1.46; 4.53]
Janz–1997	178	316	119	319	52.5%	2.14 [1.57; 2.93]
Lantz–1995	88	337	28	322	31.7%	3.32 [2.22; 4.95]
Total (95% CI)		739		751	100.0%	2.53 [2.02; 3.18]

Heterogeneity: $\text{Tau}^2 = 0.0185$; $\text{Chi}^2 = 2.84$, $\text{df} = 2$ ($P = 0.24$); $I^2 = 30\%$

Test for overall effect: $Z = 8.08$ ($P < 0.0001$)

Replicability analysis ($r\text{-value} = < 0.0001$)

Out of 3 studies, at least: 3 with increased effect and 0 with decreased effect.



Outcome: Leukopaenia: overall effect

Subgroup:

CD003366

Study	Taxane containing		Control		Weight	Risk Ratio MH, Random, 95% CI
	Events	Total	Events	Total		
ECOG-E1193-_x0028_A_x0029_	126	230	56	112	4.4%	1.10 [0.88; 1.36]
EU_x002d_93011	76	85	53	85	4.8%	1.43 [1.20; 1.72]
_x0033_06-Study-Group	202	213	184	210	5.7%	1.08 [1.02; 1.15]
AGO	69	204	89	198	4.1%	0.75 [0.59; 0.96]
Blohmer	101	125	82	111	5.2%	1.09 [0.95; 1.26]
Bonneterre	31	70	24	72	2.6%	1.33 [0.87; 2.02]
Bontenbal	96	108	90	107	5.4%	1.06 [0.95; 1.17]
CECOG-BM1	113	122	109	130	5.6%	1.10 [1.01; 1.21]
EORTC-10961	121	136	110	135	5.5%	1.09 [0.99; 1.21]
HERNATA	56	139	29	138	2.9%	1.92 [1.31; 2.81]
Jassem	119	134	87	133	5.2%	1.36 [1.18; 1.56]
Lyman	31	45	32	46	3.8%	0.99 [0.75; 1.30]
Nabholtz	224	238	192	237	5.7%	1.16 [1.08; 1.25]
Rugo	3	32	3	45	0.3%	1.41 [0.30; 6.53]
TRAVIOTA	4	40	24	41	0.8%	0.17 [0.07; 0.45]
_x0033_03-Study-Group	154	159	153	163	5.8%	1.03 [0.98; 1.08]
_x0033_04-Study-Group	188	200	176	187	5.8%	1.00 [0.95; 1.05]
ANZ-TITG	31	105	67	99	3.3%	0.44 [0.32; 0.60]
Dieras	8	38	2	39	0.4%	4.11 [0.93; 18.10]
ECOG-E1193-_x0028_B_x0029_	137	229	55	112	4.4%	1.22 [0.98; 1.51]
EORTC-10923	66	164	139	163	4.6%	0.47 [0.39; 0.57]
JCOG9802	50	147	31	146	2.9%	1.60 [1.09; 2.35]
Meier	9	58	39	62	1.5%	0.25 [0.13; 0.46]
Sjostrom	105	136	21	131	2.7%	4.82 [3.22; 7.20]
Talbot	10	19	2	22	0.4%	5.79 [1.44; 23.21]
TOG	11	97	18	96	1.3%	0.60 [0.30; 1.21]
TXT	65	79	60	90	4.8%	1.23 [1.03; 1.48]
Yardley	1	52	5	50	0.2%	0.19 [0.02; 1.59]


Total (95% CI) **3404** **3160 100.0%** **1.07 [0.97; 1.17]**

Heterogeneity: $\tau^2 = 0.0365$; $\chi^2 = 261.41$, $df = 27$ ($P < 0.01$); $I^2 = 90\%$

Test for overall effect: $Z = 1.41$ ($P = 0.1596$)

Replicability analysis (r -value = < 0.0001)

Out of 28 studies, at least: 20 with increased effect and 8 with decreased effect.



Outcome: Leukopaenia: overall effect

Subgroup: Regimen A plus taxane v Regimen B

CD003366

Study	Taxane containing		Control		Weight	Risk Ratio MH, Random, 95% CI
	Events	Total	Events	Total		
_x0033_06--Study-Group	202	213	184	210	13.4%	1.08 [1.02; 1.15]
AGO	69	204	89	198	6.0%	0.75 [0.59; 0.96]
Blohmmer	101	125	82	111	9.9%	1.09 [0.95; 1.26]
Bonneterre	31	70	24	72	2.8%	1.33 [0.87; 2.02]
Bontenbal	96	108	90	107	11.5%	1.06 [0.95; 1.17]
CECOG-BM1	113	122	109	130	12.1%	1.10 [1.01; 1.21]
EORTC-10961	121	136	110	135	11.7%	1.09 [0.99; 1.21]
HERNATA	56	139	29	138	3.3%	1.92 [1.31; 2.81]
Jassem	119	134	87	133	10.0%	1.36 [1.18; 1.56]
Lyman	31	45	32	46	5.3%	0.99 [0.75; 1.30]
Nabholtz	224	238	192	237	13.0%	1.16 [1.08; 1.25]
Rugo	3	32	3	45	0.3%	1.41 [0.30; 6.53]
TRAVIOTA	4	40	24	41	0.6%	0.17 [0.07; 0.45]

Total (95% CI)

1606

1603 100.0%


1.11 [1.02; 1.20]

Heterogeneity: $\text{Tau}^2 = 0.0112$; $\text{Chi}^2 = 45.34$, $\text{df} = 12$ ($P < 0.01$); $I^2 = 74\%$

Test for overall effect: $Z = 2.49$ ($P = 0.0128$)

Replicability analysis ($r\text{-value} = < 0.0001$)

Out of 13 studies, at least: 10 with increased effect and 3 with decreased effect.



Outcome: Leukopaenia: overall effect

Subgroup: Single agent taxane v Regimen C

CD003366


Study	Taxane containing		Control		Weight	Risk Ratio MH, Random, 95% CI
	Events	Total	Events	Total		
_x0033_03-Study-Group	154	159	153	163	12.6%	1.03 [0.98; 1.08]
_x0033_04-Study-Group	188	200	176	187	12.6%	1.00 [0.95; 1.05]
ANZ-TITG	31	105	67	99	9.5%	0.44 [0.32; 0.60]
Dieras	8	38	2	39	1.6%	4.11 [0.93; 18.10]
ECOG-E1193-_x0028_B_x0029_	137	229	55	112	11.0%	1.22 [0.98; 1.51]
EORTC-10923	66	164	139	163	11.3%	0.47 [0.39; 0.57]
JCOG9802	50	147	31	146	8.6%	1.60 [1.09; 2.35]
Meier	9	58	39	62	5.6%	0.25 [0.13; 0.46]
Sjostrom	105	136	21	131	8.3%	4.82 [3.22; 7.20]
Talbot	10	19	2	22	1.8%	5.79 [1.44; 23.21]
TOG	11	97	18	96	5.0%	0.60 [0.30; 1.21]
TXT	65	79	60	90	11.5%	1.23 [1.03; 1.48]
Yardley	1	52	5	50	0.8%	0.19 [0.02; 1.59]
Total (95% CI)		1483		1360 100.0%		0.99 [0.82; 1.21]

Heterogeneity: $\text{Tau}^2 = 0.0813$; $\text{Chi}^2 = 188.43$, $\text{df} = 12$ ($P < 0.01$); $I^2 = 94\%$

Test for overall effect: $Z = -0.05$ ($P = 0.9587$)

Replicability analysis ($r\text{-value} = < 0.0001$)

Out of 13 studies, at least: 7 with increased effect and 5 with decreased effect.



Outcome: Seroma

Subgroup:

CD006823

Study	Drain		No .		Weight	Odds Ratio MH, Random, 95% CI
	Events	Total	Events	Total		
Cameron–1988	2	20	9	20	10.0%	0.14 [0.02; 0.75]
Somers–1992	79	108	106	119	20.1%	0.33 [0.16; 0.68]
Zavotksy–1998	0	24	14	22	4.6%	0.01 [0.00; 0.22]
Purushotham–2002	98	190	98	185	23.6%	0.95 [0.63; 1.42]
Jain–2004	15	58	12	29	17.4%	0.49 [0.19; 1.27]
Soon–2005	34	36	49	51	8.1%	0.69 [0.09; 5.17]
Classe–2006	9	51	8	47	16.2%	1.04 [0.37; 2.98]


Total (95% CI) **487** **473 100.0%** **0.46 [0.23; 0.91]**

Heterogeneity: $\text{Tau}^2 = 0.4833$; $\text{Chi}^2 = 18.58$, $\text{df} = 6$ ($P < 0.01$); $I^2 = 68\%$

Test for overall effect: $Z = -2.22$ ($P = 0.0266$)

Replicability analysis ($r\text{-value} = 0.0019$)

Out of 7 studies, at least: 0 with increased effect and 6 with decreased effect.



Outcome: Cosmesis, physician-reported

Subgroup:

CD007077

Study	PBI/APBI		WBRT		Weight	Odds Ratio MH, Fixed, 95% CI
	Events	Total	Events	Total		
Livi-2015	0	246	2	260	2.5%	0.21 [0.01; 4.39]
Polg_x00e1_r-2007	24	125	43	116	37.4%	0.40 [0.23; 0.72]
RAPID	140	399	61	367	42.8%	2.71 [1.92; 3.82]
Rodriguez	12	51	8	51	6.3%	1.65 [0.61; 4.47]
TARGIT	12	55	13	50	11.0%	0.79 [0.32; 1.95]


Total (95% CI) **876** **844 100.0%** **1.51 [1.17; 1.95]**

Heterogeneity: $\text{Tau}^2 = 1.0240$; $\text{Chi}^2 = 34.47$, $\text{df} = 4$ ($P < 0.01$); $I^2 = 88\%$

Test for overall effect: $Z = 3.14$ ($P = 0.0017$)

Replicability analysis ($r\text{-value} = 0.3212$)

Out of 5 studies, at least: 2 with increased effect and 1 with decreased effect.



truncation threshold: 0.8

Outcome: Attendance to the mammogram invitation during the following 12 months

Subgroup:

CD002943

Study	Intervention		Control		Weight	Odds Ratio Peto, Fixed, 95% CI
	Events	Total	Events	Total		
Sutton–1994	576	977	167	316	32.3%	1.28 [0.99; 1.66]
Somkin–1997	310	1171	187	1171	54.2%	1.87 [1.54; 2.28]
Turnbull–1991	53	163	7	80	5.5%	3.57 [1.92; 6.63]
Mohler–1995	7	38	4	38	1.3%	1.88 [0.53; 6.68]
Bodiya–1999	36	102	37	110	6.6%	1.08 [0.61; 1.89]


Total (95% CI) **2451** **1715 100.0%** **1.66 [1.43; 1.92]**

Heterogeneity: $\text{Tau}^2 = 0.0882$; $\text{Chi}^2 = 13.47$, $\text{df} = 4$ ($P < 0.01$); $I^2 = 70\%$

Test for overall effect: $Z = 6.78$ ($P < 0.0001$)

Replicability analysis ($r\text{-value} = < 0.0001$)

Out of 5 studies, at least: 5 with increased effect and 0 with decreased effect.



Outcome: Attendance to the mammogram invitation during the following 12 months

Subgroup:

CD002943


Study	Intervention		Control		Weight	Odds Ratio Peto, Fixed, 95% CI
	Events	Total	Events	Total		
Bodiya–1999	49	86	37	110	15.8%	2.57 [1.46; 4.53]
Janz–1997	178	316	119	319	52.5%	2.14 [1.57; 2.93]
Lantz–1995	88	337	28	322	31.7%	3.32 [2.22; 4.95]
Total (95% CI)		739		751	100.0%	2.53 [2.02; 3.18]

Heterogeneity: $\text{Tau}^2 = 0.0185$; $\text{Chi}^2 = 2.84$, $\text{df} = 2$ ($P = 0.24$); $I^2 = 30\%$

Test for overall effect: $Z = 8.08$ ($P < 0.0001$)

Replicability analysis ($r\text{-value} = < 0.0001$)

Out of 3 studies, at least: 3 with increased effect and 0 with decreased effect.



Outcome: Leukopaenia: overall effect

Subgroup:

CD003366

Study	Taxane containing		Control		Weight	Risk Ratio MH, Random, 95% CI
	Events	Total	Events	Total		
ECOG-E1193-_x0028_A_x0029_	126	230	56	112	4.4%	1.10 [0.88; 1.36]
EU_x002d_93011	76	85	53	85	4.8%	1.43 [1.20; 1.72]
_x0033_06-Study-Group	202	213	184	210	5.7%	1.08 [1.02; 1.15]
AGO	69	204	89	198	4.1%	0.75 [0.59; 0.96]
Blohmer	101	125	82	111	5.2%	1.09 [0.95; 1.26]
Bonneterre	31	70	24	72	2.6%	1.33 [0.87; 2.02]
Bontenbal	96	108	90	107	5.4%	1.06 [0.95; 1.17]
CECOG-BM1	113	122	109	130	5.6%	1.10 [1.01; 1.21]
EORTC-10961	121	136	110	135	5.5%	1.09 [0.99; 1.21]
HERNATA	56	139	29	138	2.9%	1.92 [1.31; 2.81]
Jassem	119	134	87	133	5.2%	1.36 [1.18; 1.56]
Lyman	31	45	32	46	3.8%	0.99 [0.75; 1.30]
Nabholtz	224	238	192	237	5.7%	1.16 [1.08; 1.25]
Rugo	3	32	3	45	0.3%	1.41 [0.30; 6.53]
TRAVIOTA	4	40	24	41	0.8%	0.17 [0.07; 0.45]
_x0033_03-Study-Group	154	159	153	163	5.8%	1.03 [0.98; 1.08]
_x0033_04-Study-Group	188	200	176	187	5.8%	1.00 [0.95; 1.05]
ANZ-TITG	31	105	67	99	3.3%	0.44 [0.32; 0.60]
Dieras	8	38	2	39	0.4%	4.11 [0.93; 18.10]
ECOG-E1193-_x0028_B_x0029_	137	229	55	112	4.4%	1.22 [0.98; 1.51]
EORTC-10923	66	164	139	163	4.6%	0.47 [0.39; 0.57]
JCOG9802	50	147	31	146	2.9%	1.60 [1.09; 2.35]
Meier	9	58	39	62	1.5%	0.25 [0.13; 0.46]
Sjostrom	105	136	21	131	2.7%	4.82 [3.22; 7.20]
Talbot	10	19	2	22	0.4%	5.79 [1.44; 23.21]
TOG	11	97	18	96	1.3%	0.60 [0.30; 1.21]
TXT	65	79	60	90	4.8%	1.23 [1.03; 1.48]
Yardley	1	52	5	50	0.2%	0.19 [0.02; 1.59]


Total (95% CI) **3404** **3160 100.0%** **1.07 [0.97; 1.17]**

Heterogeneity: $\tau^2 = 0.0365$; $\chi^2 = 261.41$, $df = 27$ ($P < 0.01$); $I^2 = 90\%$

Test for overall effect: $Z = 1.41$ ($P = 0.1596$)

Replicability analysis (r -value = < 0.0001)

Out of 28 studies, at least: 20 with increased effect and 10 with decreased effect.



Outcome: Leukopaenia: overall effect

Subgroup: Regimen A plus taxane v Regimen B

CD003366

Study	Taxane containing		Control		Weight	Risk Ratio MH, Random, 95% CI
	Events	Total	Events	Total		
_x0033_06--Study-Group	202	213	184	210	13.4%	1.08 [1.02; 1.15]
AGO	69	204	89	198	6.0%	0.75 [0.59; 0.96]
Bloher	101	125	82	111	9.9%	1.09 [0.95; 1.26]
Bonneterre	31	70	24	72	2.8%	1.33 [0.87; 2.02]
Bontenbal	96	108	90	107	11.5%	1.06 [0.95; 1.17]
CECOG-BM1	113	122	109	130	12.1%	1.10 [1.01; 1.21]
EORTC-10961	121	136	110	135	11.7%	1.09 [0.99; 1.21]
HERNATA	56	139	29	138	3.3%	1.92 [1.31; 2.81]
Jassem	119	134	87	133	10.0%	1.36 [1.18; 1.56]
Lyman	31	45	32	46	5.3%	0.99 [0.75; 1.30]
Nabholtz	224	238	192	237	13.0%	1.16 [1.08; 1.25]
Rugo	3	32	3	45	0.3%	1.41 [0.30; 6.53]
TRAVIOTA	4	40	24	41	0.6%	0.17 [0.07; 0.45]

Total (95% CI)

1606

1603 100.0%


1.11 [1.02; 1.20]

Heterogeneity: $\text{Tau}^2 = 0.0112$; $\text{Chi}^2 = 45.34$, $\text{df} = 12$ ($P < 0.01$); $I^2 = 74\%$

Test for overall effect: $Z = 2.49$ ($P = 0.0128$)

Replicability analysis ($r\text{-value} = < 0.0001$)

Out of 13 studies, at least: 10 with increased effect and 2 with decreased effect.



Outcome: Leukopaenia: overall effect

Subgroup: Single agent taxane v Regimen C

CD003366


Study	Taxane containing		Control		Weight	Risk Ratio MH, Random, 95% CI
	Events	Total	Events	Total		
_x0033_03-Study-Group	154	159	153	163	12.6%	1.03 [0.98; 1.08]
_x0033_04-Study-Group	188	200	176	187	12.6%	1.00 [0.95; 1.05]
ANZ-TITG	31	105	67	99	9.5%	0.44 [0.32; 0.60]
Dieras	8	38	2	39	1.6%	4.11 [0.93; 18.10]
ECOG-E1193-_x0028_B_x0029_	137	229	55	112	11.0%	1.22 [0.98; 1.51]
EORTC-10923	66	164	139	163	11.3%	0.47 [0.39; 0.57]
JCOG9802	50	147	31	146	8.6%	1.60 [1.09; 2.35]
Meier	9	58	39	62	5.6%	0.25 [0.13; 0.46]
Sjostrom	105	136	21	131	8.3%	4.82 [3.22; 7.20]
Talbot	10	19	2	22	1.8%	5.79 [1.44; 23.21]
TOG	11	97	18	96	5.0%	0.60 [0.30; 1.21]
TXT	65	79	60	90	11.5%	1.23 [1.03; 1.48]
Yardley	1	52	5	50	0.8%	0.19 [0.02; 1.59]
Total (95% CI)		1483		1360 100.0%		0.99 [0.82; 1.21]

Heterogeneity: $\text{Tau}^2 = 0.0813$; $\text{Chi}^2 = 188.43$, $\text{df} = 12$ ($P < 0.01$); $I^2 = 94\%$

Test for overall effect: $Z = -0.05$ ($P = 0.9587$)

Replicability analysis ($r\text{-value} = < 0.0001$)

Out of 13 studies, at least: 7 with increased effect and 5 with decreased effect.



Outcome: Seroma

Subgroup:

CD006823

Study	Drain		No .		Weight	Odds Ratio MH, Random, 95% CI
	Events	Total	Events	Total		
Cameron–1988	2	20	9	20	10.0%	0.14 [0.02; 0.75]
Somers–1992	79	108	106	119	20.1%	0.33 [0.16; 0.68]
Zavotksy–1998	0	24	14	22	4.6%	0.01 [0.00; 0.22]
Purushotham–2002	98	190	98	185	23.6%	0.95 [0.63; 1.42]
Jain–2004	15	58	12	29	17.4%	0.49 [0.19; 1.27]
Soon–2005	34	36	49	51	8.1%	0.69 [0.09; 5.17]
Classe–2006	9	51	8	47	16.2%	1.04 [0.37; 2.98]


Total (95% CI) **487** **473 100.0%** **0.46 [0.23; 0.91]**

Heterogeneity: $\text{Tau}^2 = 0.4833$; $\text{Chi}^2 = 18.58$, $\text{df} = 6$ ($P < 0.01$); $I^2 = 68\%$

Test for overall effect: $Z = -2.22$ ($P = 0.0266$)

Replicability analysis ($r\text{-value} = 0.0021$)

Out of 7 studies, at least: 0 with increased effect and 6 with decreased effect.



Outcome: Cosmesis, physician–reported

Subgroup:

CD007077

Study	PBI/APBI		WBRT		Weight	Odds Ratio MH, Fixed, 95% CI
	Events	Total	Events	Total		
Livi-2015	0	246	2	260	2.5%	0.21 [0.01; 4.39]
Polg_x00e1_r-2007	24	125	43	116	37.4%	0.40 [0.23; 0.72]
RAPID	140	399	61	367	42.8%	2.71 [1.92; 3.82]
Rodriguez	12	51	8	51	6.3%	1.65 [0.61; 4.47]
TARGIT	12	55	13	50	11.0%	0.79 [0.32; 1.95]

Total (95% CI) **876** **844 100.0%** **1.51 [1.17; 1.95]**

Heterogeneity: $\text{Tau}^2 = 1.0240$; $\text{Chi}^2 = 34.47$, $\text{df} = 4$ ($P < 0.01$); $I^2 = 88\%$

Test for overall effect: $Z = 3.14$ ($P = 0.0017$)

Replicability analysis ($r\text{-value} = < 0.0001$)

Out of 5 studies, at least: 2 with increased effect and 1 with decreased effect.

